Form 4: C4 Therapeutics Director Donna Roy Grogan Granted 35,500 Stock Options

C4 Therapeutics, Inc. (CCCC) has reported that Director Donna Roy Grogan was granted 35,500 stock options with an exercise price of $1.44, vesting over approximately one year.

Summary

• Donna Roy Grogan, a Director of C4 Therapeutics, Inc. (CCCC), acquired 35,500 stock options on June 18, 2025.
• The exercise price for these options is $1.44 per share.
• These options are for the right to buy 35,500 shares of C4 Therapeutics Common Stock.
• The options will vest and become exercisable in full upon the earlier of June 18, 2026, or the next annual meeting of the Issuer's stockholders.
• Vesting is contingent upon Ms. Grogan's continued service as a member of the Board on the vesting date.
• Following this transaction, Ms. Grogan directly beneficially owns 35,500 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a routine compensation event, it signifies continued commitment from a director and aligns their interests with shareholders, which is generally viewed favorably.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term company performance.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The stock option grant includes a vesting schedule that extends to June 2026 or the next annual meeting, indicating an expectation of the director's continued service and contribution to the company's future.

Industry Context

Stock option grants are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, used to attract and retain talent and align their incentives with long-term shareholder value creation. This grant is a routine compensation event for a director.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology, to incentivize performance and align interests with shareholders.
• The vesting period of approximately one year is typical for such grants, often tied to continued board service or specific performance milestones.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with the company's stock performance, potentially benefiting shareholders through incentivized long-term value creation.

Next Steps

• The stock options will vest upon the earlier of June 18, 2026, or the next annual meeting of stockholders, provided the director continues her service on the board.

Key Dates

Keywords

C4 Therapeutics, CCCC, Form 4, Insider Transaction, Stock Option Grant, Director Compensation, Beneficial Ownership, Equity Incentive